Table 1.
Demographics of the clinical sample (ADNI)
| Controls | MCI | AD | Total | Statistical differences | |
|---|---|---|---|---|---|
| n | 245 | 647 | 245 | 1181 | - |
| total of scans | 610 | 2095 | 595 | 3362 | - |
| Median (IQR) of scans per participant | 3(2) | 4(3) | 3(2) | 4(3) | - |
| Follow-up time in time series data (months) mean ± sd | 37.4 ± 25.8 | 30.6 ± 24.8 | 13.9 ± 12.01 | 29.3 ± 24.5 | F(2, 603)= 34.4, P=9.6 × 10−15 |
| Sex (M:F) | 110:159 | 289:236 | 106:100 | 505:495 | X2= 14.32, P=7.6 × 10−04 |
| Baseline age mean ± sd & range | 74.8 ± 6.4 (57–93) | 73.1 ± 7.7 (55–92) | 74.4 ± 8.1 (55–91) | 73.8 ± 7.5 (55–93) | F(2, 997)=4.78, P=0.008 |
| Baseline AC score (years)† mean ± sd & range | −4.55 ± 5.8 (−15.3–9.9) | 7.23 ± 3.8 (−3.5–15.8) | 13.3 ± 2.1 (2.5–16.5) | 4.37 ± 8.52 (−15.3–16.5) | F(2, 607)=868.4, P=2.2 × 10−16 |
| MMSE score mean ± sd total & range | 28.95 ± 1.31 (22–30) | 27.78 ± 2.03 (19–30) | 22.05 ± 3.77 (5–30) | 26.89 ± 3.47 (5–30) | F(2, 845)=486.8, P=2.2 × 10−16 |
| Baseline ADNI memory mean ± sd total & range | 1.23 ± 0.62 (−0.3–3.3) | 0.39 ± 0.7 (−1.6–2.4) | −0.9 ± 06 (−2.87–0.39) | 0.35 ± 1.01 (−2.8–3.3) | F(2, 891)=604.8, P=2.2 × 10−16 |
| Baseline ADNI executive function mean ± sd total & range | 1.06 ± 0.81 (−0.9–2.9) | 0.36 ± 0.87 (−1.9–2.9) | −0.99 ± 1.06 (−3.0–2.6) | 0.28 ± 1.14 (−3.0–2.9) | F(2, 886)=279.6, P=2.2 × 10−16 |
| Baseline CSF Aβ 1–42 (pg/mL) mean ± sd total & range | 335.46 ± 386.9 (90.7–2099) | 337.89 ± 440 (82.5–2501) | 200 ± 215.6 (80.4–1286) | 300.83 ± 385.52 (80.4–2501) | F(2, 291)=3.69, P=0.03 |
| Baseline CSF p-tau (pg/mL) mean ± sd total & range | 33.07 ± 18.5 (8.8–98.5) | 38.19 ± 23.0 (8.53–121) | 58.02 ± 34.3 (12.8–188) | 42.39 ± 27.38 (8.53–188) | F(2, 290)=20.1, P=6.6 × 10−09 |
| Baseline amyloid PET SUVR mean ± sd total & range | 1.12 ± 0.23 (0.85–2.69) | 1.19 ± 0.22 (0.18–0.84) | 1.44 ± 0.19 (0.93–1.82) | 1.21 ± 0.24 (0.18–2.26) | F(2, 486)=61.0, P=2.2 × 10−16 |
| Baseline tau PET SUVR mean ± sd total & range | 1.50 ± 0.18 (1.15–2.04) | 1.56 ± 0.23 (1.21–2.41) | 1.84 ± 0.42 (1.48–2.75) | 1.56 ± 0.25 (1.15–2.75) | F(2, 104)=10.6, P=6.2 × 10−05 |
| ApoE ε4 non-carrier (proportion in group sample) | 69.0% | 57.1% | 31.2% | 55.3% | **X2= 90.41, P=2.2 × 10−16 |
Key:
*
adjusting for age, sex and ApoE ε4
**
X2 of ApoE ε4 status.
†
Disease stage score represents predicted years since amyloid PET positivity